Endocrinology and Metabolism Research Center, Department of Gynecology and Obstetrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Clin Nutr. 2019 Oct;38(5):2098-2105. doi: 10.1016/j.clnu.2018.10.028. Epub 2018 Nov 10.
This study was designed to assess the effects of combined vitamin D and probiotic supplementation on metabolic status and pregnancy outcomes in women with gestational diabetes (GDM).
This randomized, double-blind, placebo-controlled clinical trial was performed in 87 women with GDM. Patients were randomly assigned three groups to receive either vitamin D (50,000 IU/every 2 weeks) plus probiotic (8 × 10 CFU/day) (n = 30), probiotic (8 × 10 CFU/day) (n = 29) or placebo (n = 28) for 6 weeks.
Vitamin D and probiotic co-supplementation significantly reduced fasting plasma glucose (β -10.99 mg/dL; 95% CI, -14.26, -7.73; P < 0.001), serum insulin levels (β -1.95 μIU/mL; 95% CI, -3.05, -0.84; P = 0.001) and homeostasis model of assessment-insulin resistance (β -0.76; 95% CI, -1.06, -0.45; P < 0.001), and significantly increased the quantitative insulin sensitivity check index (β 0.01; 95% CI, 0.008, 0.03; P = 0.001) compared with the placebo. In addition, vitamin D and probiotic co-supplementation resulted in a significant reduction in triglycerides (β -37.56 mg/dL; 95% CI, -51.55, -23.56; P < 0.001), VLDL- (β -7.51 mg/dL; 95% CI, -10.31, -4.71; P < 0.001), HDL-/total cholesterol ratio (β -0.52; 95% CI, -0.79, -0.24; P < 0.001), high sensitivity C-reactive protein (β -1.80 mg/L; 95% CI, -2.53, -1.08; P < 0.001) and malondialdehyde (β -0.43 μmol/L; 95% CI, -0.77, -0.09; P = 0.01); also, a significant rise in HDL-cholesterol (β 4.09 mg/dL; 95% CI, 1.11, 7.08; P = 0.008) and total antioxidant capacity (TAC) levels (β 97.77 mmol/L; 95% CI, 52.34, 143.19; P < 0.001) were observed compared with the placebo. Vitamin D and probiotic co-supplementation did not change other metabolic parameters. Vitamin D and probiotic co-supplementation significantly decreased triglycerides (P = 0.02), VLDL-cholesterol (P = 0.02) and hs-CRP (P = 0.01), and significantly increased TAC (P = 0.006) and total glutathione levels (P = 0.04) compared with only probiotic group.
In conclusion, vitamin D and probiotic co-supplementation in women with GDM had beneficial effects on metabolic status. This trial was registered at www.irct.ir as IRCT201706075623N119.
本研究旨在评估维生素 D 和益生菌联合补充对妊娠期糖尿病(GDM)女性代谢状态和妊娠结局的影响。
这项随机、双盲、安慰剂对照的临床试验在 87 名 GDM 患者中进行。患者被随机分为三组,分别接受维生素 D(50,000IU/每 2 周)加益生菌(8×10CFU/天)(n=30)、益生菌(8×10CFU/天)(n=29)或安慰剂(n=28)治疗 6 周。
维生素 D 和益生菌联合补充显著降低了空腹血糖(β-10.99mg/dL;95%CI,-14.26,-7.73;P<0.001)、血清胰岛素水平(β-1.95μIU/mL;95%CI,-3.05,-0.84;P=0.001)和稳态模型评估的胰岛素抵抗(β-0.76;95%CI,-1.06,-0.45;P<0.001),并显著增加了定量胰岛素敏感性检查指数(β0.01;95%CI,0.008,0.03;P=0.001),与安慰剂相比。此外,维生素 D 和益生菌联合补充可显著降低甘油三酯(β-37.56mg/dL;95%CI,-51.55,-23.56;P<0.001)、极低密度脂蛋白(β-7.51mg/dL;95%CI,-10.31,-4.71;P<0.001)、高密度脂蛋白/总胆固醇比值(β-0.52;95%CI,-0.79,-0.24;P<0.001)、高敏 C 反应蛋白(β-1.80mg/L;95%CI,-2.53,-1.08;P<0.001)和丙二醛(β-0.43μmol/L;95%CI,-0.77,-0.09;P=0.01)水平;此外,与安慰剂相比,还观察到 HDL-胆固醇(β4.09mg/dL;95%CI,1.11,7.08;P=0.008)和总抗氧化能力(TAC)水平(β97.77mmol/L;95%CI,52.34,143.19;P<0.001)显著升高。维生素 D 和益生菌联合补充并未改变其他代谢参数。与单独使用益生菌组相比,维生素 D 和益生菌联合补充可显著降低甘油三酯(P=0.02)、极低密度脂蛋白胆固醇(P=0.02)和 hs-CRP(P=0.01)水平,并显著升高 TAC(P=0.006)和总谷胱甘肽水平(P=0.04)。
总之,维生素 D 和益生菌联合补充对 GDM 女性的代谢状态有有益的影响。本试验在 www.irct.ir 上注册,注册号为 IRCT201706075623N119。